

# New methods of follow up on urinary bladder cancer

<b>Submission date</b> 02/07/2025	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 11/08/2025	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 11/08/2025	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Background and study aims

The study aims to improve follow-up on patients diagnosed with urinary bladder cancer using endomicroscopy.

Who can participate?

Adult patients with diagnosed urinary bladder cancer stratified as pT1, who have to undergo re-ndoresection of the urinary bladder tumor.

What does the study involve?

The study involves a cystoscopy under general anesthesia - examination of the urinary bladder via urethra and intravenous application of a fluorescent agent.

What are the possible benefits and risks of participating?

The benefit of the study is to improve future follow-up of patients with pT1 bladder cancer, during a procedure that will only prolong the necessary surgery for a few minutes.

The main risk of participating is an allergic reaction to the fluorescent agent.

Where is the study run from?

The research is a part of doctoral studies at the University Hospital Brno, Czech Republic

When is the study starting and how long is it expected to run for?

April 2024 to December 2027

Who is funding the study?

The University Hospital Brno, Czech Republic

Who is the main contact?

Dr Mária Moravčíková, [moravcikova.maria@fnbrno.cz](mailto:moravcikova.maria@fnbrno.cz)

## Contact information

**Type(s)**

Public, Scientific, Principal investigator

**Contact name**

Dr Mária Moravčíková

**Contact details**

University Hospital Brno, Jihlavská 20

Brno

Czech Republic

62500

+420602613746

moravcikova.maria@fnbrno.cz

## **Additional identifiers**

**Clinical Trials Information System (CTIS)**

Nil known

**ClinicalTrials.gov (NCT)**

Nil known

**Protocol serial number**

PIG6/24

## **Study information**

**Scientific Title**

New methods of follow-up on non-muscle invasive urinary bladder cancer using confocal laser endomicroscopy

**Acronym**

UBCLEM

**Study objectives**

The study is focused on patients with non-muscle invasive urinary bladder cancer. The group of patients with histology findings pT1 are recommended to undergo a second endoresection of the bladder tumor to prevent a recurrent disease and to exclude the presence of residual tumor. During the procedure, the bladder mucosa will be examined by a confocal laser endomicroscope. This will provide a real-time microscopic imaging of the mucosa that will be used to distinguish between benign and malignant lesions. The procedure will continue with standard endoscopic repeated resection of suspicious tissue to compare the results from confocal laser endomicroscopy with histopathological results. This study aims to find out whether confocal laser endomicroscopy is precise enough compared with histopathological examination. The secondary aim is to try to prevent patients from second re-endoresection if a procedure under general anesthesia is not inevitable.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

approved 10/04/2024, Ethics Board of The University Hospital Brno (Jihlavská 20, Brno, 62500, Czech Republic; +420532232798; etickakomise@fnbrno.cz), ref: Reference number: 09-100424/EK, Project number: 52/24

**Study design**

Single-centre interventional controlled trial

**Primary study design**

Interventional

**Study type(s)**

Diagnostic, Treatment

**Health condition(s) or problem(s) studied**

Follow-up care and treatment of patients diagnosed with urinary bladder cancer.

**Interventions**

This interventional study includes patients with non-muscle invasive bladder cancer, stratified as pT1. The patients will undergo a standard second re-endorsement of the urinary bladder tumor. Before this procedure under general anesthesia, the mucosa of the bladder will be examined with laser confocal endomicroscopy. This examination will provide real-time visualisation of atypical mucosa and submucosa cells. A fluorescent agent is administered intravenously shortly before examination to aid visualisation.

**Intervention Type**

Procedure/Surgery

**Primary outcome(s)**

Malign and benign lesions during re-endorsement of urinary bladder tumor will be measured using laser confocal endomicroscopy at one time point

**Key secondary outcome(s)**

Confirmation between benign and malignant lesions will be undertaken after the examination by laser confocal endomicroscopy, using histopathological examination at one time point

**Completion date**

31/12/2027

**Eligibility****Key inclusion criteria**

Patients with diagnosed urinary bladder cancer stratified as pT1, who have to undergo re-endorsement of the urinary bladder tumor.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

100 years

**Sex**

All

**Key exclusion criteria**

First histological examination without detection of muscle tissue (pTX), incomplete first resections.

**Date of first enrolment**

01/09/2025

**Date of final enrolment**

31/12/2027

**Locations****Countries of recruitment**

Czech Republic

**Study participating centre**

University Hospital Brno

Jihlavská 20

Brno

Czech Republic

62500

**Sponsor information****Organisation**

University Hospital Brno

**ROR**

<https://ror.org/00qq1fp34>

**Funder(s)**

**Funder type**

University/education

**Funder Name**

University Hospital Brno

**Funder Name**

Masarykova Univerzita

**Alternative Name(s)**

Masaryk University, MU

**Funding Body Type**

Government organisation

**Funding Body Subtype**

Local government

**Location**

Czech Republic

## Results and Publications

**Individual participant data (IPD) sharing plan**

Identifiable patient data will not be available or shared with a third party. The data-sharing plans for the current study are unknown and will be made available at a later date.

**IPD sharing plan summary**

Available on request

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes